Audit: QRS - Rose Hip for Health & Longevity
Audit conducted on 21/10/2026 04:21 using AI4L + evidence-mcp / GPT 6 Astra
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 89 |
| Failed | 0 |
| N/A | 5 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Claims and regimens trace to ER benefits, risks, protocol, monitoring and conclusion; no additional clinical claim. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Preserves preparation dependence, theoretical interactions, precautionary pregnancy avoidance and pragmatic monitoring caveats. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No longevity benefit asserted; assessment windows are not promised onset; pregnancy avoidance remains precautionary. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Benefits, adverse effects, contraindications and interactions remain in their source categories. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | Named interaction examples amlodipine, insulin and warfarin occur for the same facts in ER lines 352–354. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No new study, expert or product attribution. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s cautious, formulation-specific assessment. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Objective summary with practical outcomes and limitations, without alarmism. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Describes trial approaches and observations rather than prescribing treatment. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Doses are explicitly trial approaches; no individualized treatment instruction. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Presents evidence and reference practice rather than recommendations. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | Variable content does not address the reader; fixed template disclaimer retained. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain-language outcomes; required technical product and biomarker terms remain specific. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Compact cells, short gate entries and tiered lists. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct address introduced into variable content. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Activity, meaningful outcomes and uncertainty are framed for health-focused adults. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Presents sustained dosing and monitoring without assuming inconvenience is disqualifying. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Focuses on defined experiments and measurable response, not indiscriminate public use. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Preserves the limited applicability of diabetes and postoperative findings. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | Uses longevity and longer-life framing, not anti-aging marketing. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Uses orally, doses, medications and formal scientific terminology. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: | 🟢 | All fixed card, gate, tier and monitoring headings retained. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Source comparison confirms every template data-qrs-var anchor remains present. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Only checklist-addressed variable regions populated; fixed website anchors retained. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | 🟢 | No unsupported empty-state text; absent tiers hidden as specifically required by 12.5 and 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol and qualitative labels retain ER wording; interaction dash clauses stripped under 9.4 and examples trimmed under 9.5. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels derive from ER headings, table rows or bold bullet labels; permitted concise gate trimming does not invent labels. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators in the QRS. |
| 4.5 | The QRS is designed to render on one A4 page: every section is condensed to the shortest form the other checklist items allow, not extended onto a second page. | 🟢 | Required lists condensed; no citations, effect-size elaboration or unnecessary example lists. Source-only assessment. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is first after the doctype. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Single YAML block has opening and closing delimiters. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Metadata remains inside the HTML comment. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed; duration quoting is permitted because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Source ER basename matches the read-only staging ER. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | QRS prompt version 26.10.18 matches the guideline. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Creation timestamp 2026-1021-0414 uses the required format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Creator nickname is present as GPT-Astra. |
| 5.9 | The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT) | 🟢 | GPT-Astra is GPT 6 Astra without the version, with remaining words hyphenated. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Creator full name is present as GPT 6 Astra. |
| 5.11 | The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y) | 🟢 | Full name agrees with the explicitly supplied GPT-6 Astra model identity. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Metadata QRS filename matches the target basename. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | No unnecessary quoting or leading/trailing value whitespace. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Title matches canonical_topic plus the prescribed suffix; ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Header matches ER canonical_topic with ampersand encoded. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 10/21/2026 agrees with the creation date. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Header model matches creator full name. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Only template header elements and prescribed substitutions appear. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens with plant-derived supplement and joint symptom relief. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER conclusion lines 458–462 into practical benefit, harm and formulation considerations. |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | At-a-glance text contains 59 whitespace-delimited words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Intervention/use: ER 36, 458; uncertainty and activity: 458–460; risks and defined outcomes: 462. |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No specialist acronym or technical classification in the lede. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, dates, sample sizes or p-values. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numerical effects, relative risks or statistical results. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from avoidance populations in ER lines 359–362. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Includes known allergy and precautionary concentrated supplementation avoidance during pregnancy/breastfeeding. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Both contraindications are li elements. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Only the key conditions and decision-relevant precautionary qualifier remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Concentrated-supplement and precautionary scope preserved; no source threshold omitted. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No source ranking notation requires normalization. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section populated because the ER identifies avoidance populations. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from ER interaction bullets at lines 350–357. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eight interaction categories represented; no duplication of avoidance populations. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each interaction is an li element. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanistic explanations and dash-delimited management clauses removed. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Theoretical qualifiers retained and each parenthetical example list keeps an example; anticoagulant gloss shortened to warfarin. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No source severity-ranking symbol requires conversion. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section populated because interactions are identified in the ER. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Protocol content derives from ER lines 384, 388 and 390. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Covers main joint-powder regimen, distinct extract regimen and dosing timing; avoids conflating preparations. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER contains at least three distinct implementation aspects. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All action cells contain supported dose, formulation, duration or timing information. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Includes both Medium outcomes and the principal joint-symptom outcome with their assessment windows. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Prioritizes the two substantial condition-specific controlled signals, then modest/conflicted joint benefit; unlike endpoints do not support a precise cross-outcome numerical ranking. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | At least three distinct assessment windows are available. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Four weeks: ER 159; days 7–10 and 20: ER 167; joint 3–4 months: ER 414. Caveats preserve population and onset limits. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Benefits reproduce ER Expected Benefits tiers and outcome headings. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four benefits anchors present. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Outcome descriptors only; no explanatory paragraphs or numerical effects. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical study or effect detail retained in benefit lists. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | High tier hidden with display: none because ER identifies no High benefit. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Risk tiers reproduce ER Potential Risks & Side Effects headings. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four risk anchors present. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Concise risk descriptors only; raw-fruit and multi-herb wording identifies the actual risk rather than adding explanation. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical frequencies, grades or study details retained. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | High and Medium risk spans hidden with display: none. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Monitoring derives from ER lines 431–438. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | Both listed measurable biomarkers included: resting pressure and low-density lipoprotein cholesterol. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Baseline, weekly tolerance, pressure 2–6 weeks, cholesterol 6–12 weeks and joint/activity baseline/6/12 weeks preserved with pragmatic caveat. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Qualitative entries derive from ER lines 440–442. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Includes joint pain, stiffness, walking, rescue-medication use, stool changes, nausea, rash, dizziness, sleep and energy. |
Issues 21/10/2026 04:21
Pass rate 100.00%. No issues found.
Issues 21/10/2026 04:18
- 4.5 / 8.4 — Redundant contraindication explanation: QRS line 541 repeats the precautionary qualifier with “not a demonstrated absolute contraindication.” Retain pregnancy/breastfeeding, concentrated supplementation, and precautionary avoidance while removing this trailing explanation.
Fixes 21/10/2026 04:18
- 4.5 / 8.4 — Redundant contraindication explanation: Removed “not a demonstrated absolute contraindication.” Preserved pregnancy/breastfeeding, concentrated supplementation, and precautionary avoidance in a compact parenthetical qualifier.
Issues 21/10/2026 04:16
- 11.2 — Time window magnitude prioritization: The Time to effect panel includes joint and metabolic outcomes but omits the postoperative urine-culture outcome, despite its substantial reported odds reductions at days 7–10 and 20 (ER lines 163–167). The selection does not consistently prioritize magnitude of related benefit.
Fixes 21/10/2026 04:16
- 11.2 — Time window magnitude prioritization: Replaced the metabolic assessment cell with the postoperative urine-culture assessment windows and moved joint outcomes to the third cell. Preserved the distinction between reduced positive cultures and the absence of significant symptomatic bladder-infection reduction.